Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Efavirenz. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 10/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | CCKBR | P32239 | 1/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Efavirenz SCHEMBL1560709 | 1.00 | CYP46A1 (1.00) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| Efavirenz SCHEMBL37762 | 1.00 | CYP46A1 (1.00) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| Efavirenz SCHEMBL13098636 | 1.00 | CYP46A1 (1.00) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| Efavirenz SCHEMBL464769 | 1.00 | CYP46A1 (1.00) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| Efavirenz SCHEMBL28518509 | 0.99 | CYP46A1 (0.98) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| Efavirenz SCHEMBL28400913 | 0.99 | CYP46A1 (0.98) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| Efavirenz SCHEMBL5576237 | 0.99 | CYP46A1 (0.98) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| Efavirenz SCHEMBL28777926 | 0.99 | CYP46A1 (0.98) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| Efavirenz SCHEMBL5028560 | 0.95 | CYP46A1 (0.90) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| Efavirenz SCHEMBL28698666 | 0.92 | CYP46A1 (0.84) | CYP46A1NR1I2NR3C1PGRADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113712963-A | Application of BET inhibitor BMS-986158 in preparation of anti-AIDS drugs | 中国科学院昆明动物研究所 | 2021-11-30 | — | — | CN | claimed |
| CN-116178292-A | Fluoroalkyl and aza group substituted nucleoside analogue precursor, its synthesis method and medical use | 吴卫东 | 2023-05-30 | — | — | CN | disclosed |
| CN-113712963-B | Application of BET inhibitor BMS-986158 in preparation of anti-AIDS drug | 中国科学院昆明动物研究所 | 2022-09-23 | — | — | CN | disclosed |
| CN-113712963-A | Application of BET inhibitor BMS-986158 in preparation of anti-AIDS drugs | 中国科学院昆明动物研究所 | 2021-11-30 | — | — | CN | disclosed |
| EP-3478324-A1 | ANTIBODY-DRUG CONJUGATES AND THERAPEUTIC METHODS USING THE SAME | GlaxoSmithKline Intellectual Property (No.2) Limited (GB) | 2019-05-08 | — | — | EP | disclosed |
| WO-2019014420-A1 | COMPOSITIONS AND METHODS OF DECREASING MEDICATION ERRORS | AZHC, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| EP-3328875-A1 | BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2018-06-06 | — | — | EP | disclosed |
| EP-3317271-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2018-05-09 | — | — | EP | disclosed |
| WO-2018002902-A1 | ANTIBODY-DRUG CONJUGATES AND THERAPEUTIC METHODS USING THE SAME | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-01-04 | — | — | WO | disclosed |
| EP-3261441-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVES | Neonc Technologies Inc. (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2006040643-A2 | POLYMORPHIC FORMS OF EFAVIRENZ AND PROCESSES FOR THEIR PREPARATION | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006030299-A1 | PROCESSES FOR THE PREPARATION OF POLYMORPHS OF EFAVIRENZ | RANBAXY LABORATORIES LIMITED (IN) | 2006-03-23 | — | — | WO | disclosed |
| EP-1480772-A4 | METHODS FOR QUALITATIVE AND QUANTITATIVE ANALYSIS OF CELLS AND RELATED OPTICAL BIO-DISC SYSTEMS | BURSTEIN TECHNOLOGIES INC (US) | 2005-08-17 | — | — | EP | disclosed |
| CN-1592684-A | Methods for qualitative and quantitative analysis of cells and related optical bio-disc systems | BURSTEIN TECHNOLOGIES INC (US) | 2005-03-09 | — | — | CN | disclosed |
| EP-1480772-A2 | METHODS FOR QUALITATIVE AND QUANTITATIVE ANALYSIS OF CELLS AND RELATED OPTICAL BIO-DISC SYSTEMS | Burstein Technologies, Inc. (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040204498-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| WO-2004062613-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20030129665-A1 | Methods for qualitative and quantitative analysis of cells and related optical bio-disc systems | VINDUR TECHNOLOGIES, INC. (NO) | 2003-07-10 | — | — | US | disclosed |
| US-20030092145-A1 | Viral vaccine composition, process, and methods of use | IMMUNITOR USA INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003021223-A2 | METHODS FOR QUALITATIVE AND QUANTITATIVE ANALYSIS OF CELLS AND RELATED OPTICAL BIO-DISC SYSTEMS | BURSTEIN TECHNOLOGIES, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204498-A1 | HIV integrase inhibitors | IMPDH1, TYMP, REV1 | CYP46A1 767/4885NR1I2 838/4885NR3C1 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.